Related Experiment Video
Updated: May 20, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Association between XPF polymorphisms and cancer risk: a meta-analysis
Ting-Yan Shi1, Jing He, Li-Xin Qiu
1Cancer Research Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Plos One
|July 7, 2012
Summary
Xeroderma pigmentosum complementation group F (XPF) gene variants are not linked to overall cancer risk. However, XPF-rs1799801 may reduce cancer risk in Caucasians, requiring further validation.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- Xeroderma pigmentosum complementation group F (XPF) is crucial for DNA repair, preventing genetic instability and cancer.
- Previous studies on XPF polymorphisms and cancer risk have yielded inconclusive results.
Purpose of the Study:
- To conduct a meta-analysis evaluating the association between common XPF gene polymorphisms and overall cancer risk.
- To investigate potential associations in specific populations and genotypes.
Main Methods:
- A meta-analysis of 43 case-control studies (47,639 cases, 51,915 controls) examining four XPF polymorphisms (rs1800067, rs1799801, rs2020955, rs744154).
- Data sourced from MEDLINE, EMBASE, and CNKI databases.
- Stratification and genotype-phenotype correlation analyses were performed.
Main Results:
- No significant association was found between the four XPF single nucleotide polymorphisms (SNPs) and overall cancer risk.
- A significant association between XPF-rs1799801 and reduced cancer risk was observed in Caucasian populations (recessive model: OR=0.87).
- Homozygous variant CC genotype carriers exhibited higher XPF expression compared to TT genotype carriers (P=0.046).
Conclusions:
- The meta-analysis found no statistical evidence linking the studied XPF SNPs to overall cancer risk.
- XPF-rs1799801 may be associated with cancer risk in Caucasian populations.
- Further validation in large prospective studies is warranted for XPF-rs1799801 findings.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...